The goal of this clinical trial is to see if receiving chatbot-delivered stage-of-change-tailored online interventions is effective in reducing chemsex among men who have sex with men in Hong Kong. The main question it aims to answer is: Does chatbot-delivered stage-of-changed online interventions reduce chemsex among men who have sex with men Eligible you would be randomly assigned to either the intervention or the control group.
Official registry: https://clinicaltrials.gov/study/NCT07472582 · Chinese University of Hong Kong · enrollment listed as 100
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are Chatbot-delivered online interventions and online videos, or Online videos only. The registry lists allocation as randomized. The goal of this clinical trial is to see if receiving chatbot-delivered stage-of-change-tailored online interventions is effective in reducing chemsex among men who have sex with men in Hong Kong.
They plan to enroll about 100 people at Hong Kong. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.
A Chatbot to Reduce Chemsex and HIV-related Risk Behaviors Among Men Who Have Sex With Men: a Pilot Randomized Controlled Trial
Interventions: Chatbot-delivered online interventions and online videos, Online videos only
Primary outcome (registry wording): Presence of chemsex in the past 3 months
Zixin Wang, PhD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.
NCT00001238 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.
NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.
NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary